Article contents
Late-onset liver abnormalities associated with long-term lofepramine treatment
Published online by Cambridge University Press: 13 June 2014
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

- Type
- Letters to the Editor
- Information
- Copyright
- Copyright © Cambridge University Press 1996
References
1.Feighner, JP, Meredith, CH, Dutt, JE, Henrickson, G. A double-blind comparison of lofepramine, imipramine and placebo in patients with primary depression. Acta Psychiatrica Scand 1982; 66: 109–20.CrossRefGoogle Scholar
2. Anonymous. Lofepramine (Gamanil) and abnormal blood tests of liver function. Committee on Safety of Medicines. Current Problems 1988; 23: 371.Google Scholar
3.Kelly, C, Roche, S, Naguib, M, Webb, S, Roberts, M, Pitt, B. A prospective evaluation of the hepatotoxicity of lofepramine in the elderly. Int Clin Psychopharmacol 1993; 8: 83–6.CrossRefGoogle ScholarPubMed
4.Price, LH, Nelson, JC, Waltrip, RW. Desipramine-associated hepatitis. J Clin Psychopharmacol 1983; 3(4): 243–46.CrossRefGoogle ScholarPubMed
5.Lack, SJ, Baldwin, DS, Montgomery, SA. Lofepramine, desipramine and abnormal tests of liver function: a case report. Int Clin Psychopharmacol 1990; 5: 185–90.CrossRefGoogle ScholarPubMed
- 1
- Cited by